A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. ("Dyadic", or the "Company") (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic partnership for the...
GARDNER, Mass., Feb. 8, 2024 -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that it has scheduled a conference call to...
PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the...
Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023. Reports GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.39 for the fourth quarter of 2023. Reports GAAP diluted EPS of $1.35 and non-GAAP diluted EPS...
DENVER, CO / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period...
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an...
Virtual event on Thursday, February 15, 2024 at 12:00 PM ET will feature KOLs Larry Ereshefsky, PharmD, BCPP, FCCP, of Follow the Molecule and Mark Opler, PhD, MPH of WCGCUPERTINO, Calif., Feb. 06, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva"...
FDA has set a target action date of October 4, 2024sNDA supported by two Phase 1 safety studies1Aims at actinic keratosis (AK) field treatment with up to 3 tubesAn estimated 13 million treatments given each year for AK in the US2WOBURN, MA / ACCESSWIRE / February 5,...
CARLSBAD, Calif., Feb. 05, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its second United States Patent...
This KOL Panel features Bill Maughan, Direct, Senior Analyst at Canaccord Genuity Group joins Lytham Vice President, Ben Shamsian for a deep dive into market trends within the cancer industry. This KOL Panel was recorded during the Lytham Partners 2024 Investor Select...
This KOL Panel features Brooks O'Neil, Senior Research Analyst at Lake Street Capital Markets joins Lytham Managing Partner, Joe Dorame for a deep dive into market trends within the medical device sector. This KOL Panel was recorded during the Lytham Partners 2024...
During this company webcast, we welcome Iradimed Corporation, which trades on the NASDAQ under the ticker IRMD. Joining us from the company is, Jack Glenn, Chief Financial Officer. Before This Company Webcast was recorded during the Lytham Partners 2024 Investor...
During this fireside chat webcast, we welcome Delcath Systems, ticker symbol DCTH on the NASDAQ. Joining us today from the company is Gerard Michel, Delcath's Chief Executive Officer. Also joining us today is Bill Maughan, Senior Research Analyst with Canaccord...
During this company webcast, we welcome Zomedica, ticker symbol of ZOM on the NYSE American. And joining us today from the company is Larry Heaton, Zomedica’s Chief Executive Officer. This Company Webcast was recorded during the Lytham Partners 2024 Investor Select...
During this fireside chat webcast, we welcome Shuttle Pharmaceuticals, ticker symbol of SHPH on the Nasdaq. And joining us today from the company is their Chief Executive Officer, Dr. Dritschilo. This Fireside Chat was recorded during the Lytham Partners 2024 Investor...
During this fireside chat, we welcome Precision Optics, ticker symbol of POCI on the NASDAQ. And joining us from the company as always is Dr. Joe Forkey, the company's Chief Executive Officer. This Fireside Chat was recorded during the Lytham Partners 2024 Investor...
During this fireside chat webcast, we welcome Reviva Pharmaceuticals, ticker symbol RVPH on the NASDAQ. Joining us today from the company is Lax Bhat, Reviva's Chief Executive Officer. Also joining us is Jim Molloy, Senior Research Analyst with Alliance Global...
Syra is a medically oriented professional services company that leverages deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcomes. This Company Webcast was...
In this discussion, we welcome Aytu BioPharma, NASDAQ ticker symbol AYTU. And with us today is their Chief Executive Officer, Josh Disbrow. This Fireside Chat was recorded during the Lytham Partners 2024 Investor Select Conference.
During this fireside chat we welcome Cadrenal Therapeutics, ticker symbol of CVKD on the Nasdaq. Joining us from the company is the company’s Chief Medical Officer, Dr. Douglas Losordo. Also joining us is Joe Pantginis. Joe is the Managing Director of Research at H.C....
WINTER SPRINGS, Fla., Feb. 01, 2024 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call...
JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction...
During this fireside chat webcast, we welcome Jaguar Health, ticker symbol of JAGX on the Nasdaq. And joining us from the come company is the company’s Chief Executive Officer, Lisa Conte. This Fireside Chat was recorded during the Lytham Partners 2024 Investor Select...
During this company webcast, we welcome Electromed, Inc., ticker Symbol ELMD, trading on the NASDAQ. Joining us today from the company are Jim Cunniff, President and Chief Executive Officer; and Brad Nagel, Chief Financial Officer. Also joining us today is Brooks...
For this fireside chat, we welcome Dyadic Inc., which trades on the NASDAQ under the tickler DYAI. Joining us from the company are Mark Emalfarb, Chief Executive Officer; and Joe Hazelton, Chief Business Officer, to give us an overview of the company. This Fireside...
PONTE VEDRA, Fla., Jan. 31, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, cited today a recent...
NEW YORK, Jan. 31, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Centers for Medicare & Medicaid Services ("CMS") has established a...
CARMEL, Ind., Jan. 31, 2024 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the...
CARLSBAD, Calif., Jan. 29, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its United States Patent No:...
PONTE VEDRA, Fla., Jan. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths...
GARDNER, Mass., Jan. 23, 2024 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that Dr. Joe Forkey, Chief Executive Officer, will...
DENVER, CO / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings...
NEW YORK, Jan. 23, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that Gerard Michel, CEO, will participate in a fireside chat moderated by Bill...
DENVER, CO / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings...
CARLSBAD, Calif., Jan. 18, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that it will be participating in...
NEW YORK, Jan. 16, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the first commercial use of HEPZATO KIT for the treatment of metastatic uveal...
NEW YORK, Jan. 12, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously...
WOBURN, MA / ACCESSWIRE / January 11, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and twelve months ended December...
Reports preliminary fourth quarter 2023 revenue of $17.5 million WINTER SPRINGS, Fla., Jan. 09, 2024 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging ('MRI") compatible medical devices, today reported...
PORTLAND, Maine, Jan. 08, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
NEW YORK, NY / January 8, 2024 / Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK:DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a...
CARLSBAD, Calif., Jan. 08, 2024 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that it will be attending the J.P....
PONTE VEDRA, Fla., Jan. 4, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths...
WINTER SPRINGS, Fla., Jan. 02, 2024 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging ("MRI") compatible medical devices, today announced that the Company will be participating in the upcoming 42nd...
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction...
CARMEL, Ind., Dec. 20, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today issued a letter to...
PONTE VEDRA, Fla., Dec. 19, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths...
PONTE VEDRA, Fla., Dec. 12, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage, novel, oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths...
WINTER SPRINGS, Fla., Dec. 12, 2023 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company's outstanding...
Abstract from 2023 American Society of Hematology (ASH) MeetingData demonstrates differentiated profile from DARZALEX® (daratumumab) with best-in-class potential, supports initiation of clinical trials in 2024NAYA expects to close its previously announced merger...